Form 4: Centessa Pharmaceuticals Chief Business Officer Exercises Options and Sells Shares Under 10b5-1 Plan

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, exercised stock options and subsequently sold 10,000 ordinary shares for a significant gain, as disclosed in a recent SEC Form 4 filing.

Summary

• Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc (CNTA), reported a transaction on May 27, 2025, involving the company's ordinary shares.
• He exercised options to acquire 10,000 ordinary shares at an exercise price of $3.85 per share.
• Concurrently, Mr. Weinhoff sold 10,000 ordinary shares at a weighted average price of $12.8225 per share.
• The sales were executed in multiple transactions with prices ranging from $12.62 to $13.17 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Weinhoff on May 22, 2024.
• Following these reported transactions, Mr. Weinhoff's direct beneficial ownership of ordinary shares stands at 122,279, and he retains 75,000 share options.

Sentiment

Score: 6

Explanation: The transaction itself is neutral, representing a planned executive sale for liquidity and diversification. The execution under a 10b5-1 plan is a positive for compliance and transparency. The executive realized a significant personal gain, which is positive for the individual, but the sale does not inherently signal strong positive or negative company performance.

Positives

• The Chief Business Officer realized a substantial gain of approximately $8.97 per share from the exercise and sale of shares, totaling $89,725.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a planned and compliant sale for personal liquidity or diversification rather than a reaction to immediate market conditions.

Negatives

• While common, the sale of shares by an executive, even under a 10b5-1 plan, could be interpreted by some investors as a slight reduction in insider confidence, though this is a routine practice.

Risks

• This Form 4 filing primarily reports an insider transaction and does not contain information regarding specific operational, financial, or strategic risks of Centessa Pharmaceuticals plc.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Centessa Pharmaceuticals plc's future performance, strategic initiatives, or financial outlook, as its sole purpose is to report insider transactions.

Management Comments

• The filing includes a standard legal undertaking by the Reporting Person to provide the Issuer, any security holder, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the reported range.

Industry Context

This filing is a routine insider transaction report for an executive at a pharmaceutical company. It does not offer insights into broader industry trends, competitive dynamics, or specific developments within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• As a Form 4 filing, this document reports an individual executive's stock transactions and does not provide information suitable for comparison to industry-wide financial benchmarks, project results, or specific comparable companies. Such comparisons are typically found in comprehensive financial reports or industry analyses.

Stakeholder Impact

• Shareholders: The sale by an executive, even under a 10b5-1 plan, could be viewed neutrally or with slight concern depending on individual interpretation. However, the executive's continued significant holding of shares and options suggests ongoing alignment with shareholder interests.

Next Steps

• The document does not mention any specific future actions, events, or milestones for Centessa Pharmaceuticals plc. It is a historical report of a completed transaction.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1, Chief Business Officer, Gregory M. Weinhoff, Biotechnology, Pharmaceuticals